{"id":506091,"date":"2020-09-09T13:28:01","date_gmt":"2020-09-09T13:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506091"},"modified":"2020-09-09T13:28:01","modified_gmt":"2020-09-09T13:28:01","slug":"sanuwave-ceo-to-present-at-the-global-chinese-financial-forum-thursday-september-10-2020-message-targets-transformative-acquisition-of-celularitys-ultramist","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sanuwave-ceo-to-present-at-the-global-chinese-financial-forum-thursday-september-10-2020-message-targets-transformative-acquisition-of-celularitys-ultramist_506091.html","title":{"rendered":"SANUWAVE CEO To Present At “The Global Chinese Financial Forum” Thursday, September 10, 2020; Message Targets Transformative Acquisition Of Celularity\u2019s UltraMIST\u00ae"},"content":{"rendered":"

SANUWAVE (OTCMKTS: SNWV<\/a>) CEO Kevin Richardson II is back on the road following last week’s presentation at the LD Micro 500 virtual conference. On Thursday, September 10, 2020, Mr. Richardson will be presenting at The Global Chinese Financial Forum at 11:15 am PST (2:15 pm ET). <\/strong>The event will include a formal corporate presentation and one-on-one investor meetings.<\/p>\n

The presentation is expected to detail how the addition of Celularity’s UltraMIST® is a transformative event for SANUWAVE. The remaining three investor presentations planned for September will likely follow a similar theme- the acquisition created a transformative and game-changing moment for SANUWAVE.<\/p>\n

Following the conclusion of the LD Micro event, shares of SANUWAVE traded higher by more than 5% as investors digested the news that more than $15 million in accretive revenues and $4 million in EBITDA will likely be added to its yearly run-rate. The company also noted that it is well into the process of listing to a more senior exchange with an update expected in the next thirty days. <\/p>\n

At the LD conference, SANUWAVE discussed the value drivers behind the UltraMIST® acquisition. Besides the immediately accretive acquisition of UltraMIST®, the company also secured premium licensing terms for two important biologics, Biovance and Interfyl, creating a comprehensive wound-care treatment platform that can effectively treat patients from discovery to closure. Additionally, an enhanced and trained sales force of roughly 100 people can immediately maximize and cross-sell the combined strength and complementary nature of UltraMIST® and dermaPACE®, SANUWAVE’s flagship device.<\/p>\n

SANUWAVE expects to seize the cross-selling opportunities from roughly 1000 customer accounts with only 15 that overlap to create a ramp in revenues in the current quarter. Moreover, revenue growth is expected to accelerate in the coming quarters and benefit from cost savings and economies of scale. In the Q&A following the presentation, Mr. Richardson said that he believes the company can reach a $100 million revenue run rate in roughly three years. <\/p>\n

Following tomorrow’s event, SANUWAVE will be at the HC Wainwright 22nd Annual Global Investment Conference <\/strong>on Wednesday, September 16, 2020, and will present at 4:00 pm ET.<\/strong> <\/strong> (see schedule and link to all events below)<\/p>\n

 <\/p>\n

Busy Presentation Schedule In September<\/strong><\/p>\n

SANUWAVE is scheduled to present at four major virtual investor conferences this month. The message is expected to help investors understand the true value behinds this game-changing acquisition for SANUWAVE. It may also tighten the valuation disconnect between current stock price levels that neglect the enormous boost to revenues and EBITDA earnings. <\/p>\n

 <\/p>\n

The September 2020 presentation schedule includes:<\/strong><\/p>\n

 <\/p>\n

Completed<\/strong> – The LD Micro 500 <\/em>– <\/em>Listen to the presentation HERE<\/a><\/strong><\/p>\n

Dates: September 1 – 4, 2020 <\/em><\/p>\n

Company presentation: Wednesday, September 2, 2020, at 8:40 am ET<\/em><\/p>\n

Format: Corporate presentation and One-on-One Investor Meetings<\/em><\/p>\n

 <\/p>\n

The Global Chinese Financial Forum-Investing in Innovation<\/strong><\/p>\n

Dates: September 10, 2020<\/p>\n

Company presentation: Thursday, September 10, 2020, at 11:15 am PST (2:15 pm ET)<\/p>\n

Format: Corporate presentation and One-on-One Investor Meetings<\/p>\n

 <\/p>\n

HC Wainwright 22nd Annual Global Investment Conference <\/strong><\/p>\n

Dates: September 15-16, 2020<\/p>\n

Company Presentation: Wednesday, September 16, 2020, at 4:00 pm ET<\/p>\n

Format: Corporate presentation and One-on-One Investor Meetings<\/p>\n

 <\/p>\n

Lake Street Capital Markets 4th Annual Best Ideas Growth Conference (Big 4) <\/strong><\/p>\n

Dates: September 17, 2020<\/p>\n

Format: One-on-One Investor Meetings<\/p>\n

 <\/p>\n

Each presentation will be webcast live and is accessible through the Events section of SANUWAVE Health’s website at www.SANUWAVE.com<\/a>, where they will also be archived.<\/p>\n

SANUWAVE’s message is one of transformation for the company. The virtual conferences provide a forum for SANUWAVE to highlight the substantial growth opportunities inherent to its acquisition of Celularity’s UltraMIST® assets. Further, SANUWAVE can show competitive differences and advantages compared to industry giants like Procter & Gamble (NYSE: PG<\/a>) and Medtronic (NYSE: MDT<\/a>). Medtronic reported revenues of more than $550 million from its diabetes group during its recently completed quarter, a number that demonstrates just a portion of the market opportunities for SANUWAVE.<\/p>\n

The message delivered at LD Micro was powerful. Simply stated, management explained that the transformative acquisition provides SANUWAVE with a platform of scale, immediately brings substantial recurring revenue, and gives SANUWAVE an end-to-end advanced wound care product portfolio. The entirety of that platform addresses the entire care pathway and is compelling to patients, providers, and payers.<\/p>\n

Few, if any, other companies in the sector currently offer such a comprehensive treatment solution.<\/p>\n

 <\/p>\n

Disclaimers: Blue Hawk Media, LLC is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. The information made available by Blue Hawk Media, LLC is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Blue Hawk Media, LLC be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Blue Hawk Media, LLC, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. This video and its release is to syndicated outlets has been produced through the engagement of a third party, SANUWAVE, Inc., who has hired Blue Hawk Media, LLC to prepare a research and video report for SANUWAVE. The company has compensated Blue Hawk Media, LLC three-thousand-five-hundred dollars to prepare original content, video production , and syndication services. <\/em><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Blue Hawk Media, LLC<\/a>
Contact Person:<\/strong> Kenny Ellis
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.soulstringmedia.com<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

SANUWAVE (OTCMKTS: SNWV) CEO Kevin Richardson II is back on the road following last week’s presentation at the LD Micro 500 virtual conference. On Thursday, September 10, 2020, Mr. Richardson will be presenting at The Global Chinese Financial Forum at 11:15 am … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,437,406],"tags":[],"class_list":["post-506091","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Lifestyle","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=506091"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506091\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=506091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=506091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=506091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}